Skip to main content
Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · Real-Time Price · USD
12.17
+0.16 (1.33%)
Nov 20, 2024, 4:00 PM EST - Market closed

Dynavax Technologies Revenue

Dynavax Technologies had revenue of $80.63M in the quarter ending September 30, 2024, with 15.99% growth. This brings the company's revenue in the last twelve months to $260.81M, down -27.79% year-over-year. In the year 2023, Dynavax Technologies had annual revenue of $232.28M, down -67.86%.

Revenue (ttm)
$260.81M
Revenue Growth
-27.79%
P/S Ratio
6.09
Revenue / Employee
$639,240
Employees
408
Market Cap
1.60B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023232.28M-490.40M-67.86%
Dec 31, 2022722.68M283.24M64.45%
Dec 31, 2021439.44M399.19M991.75%
Dec 31, 202040.25M5.03M14.29%
Dec 31, 201935.22M27.02M329.60%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Teladoc Health 2.59B
InMode 423.75M
BioCryst Pharmaceuticals 412.58M
Kiniksa Pharmaceuticals International, 384.10M
Certara 372.80M
Immunocore Holdings 296.31M
Travere Therapeutics 203.45M
Nurix Therapeutics 56.42M
Revenue Rankings

DVAX News

More News